Long-term results of stem cell transplantation for MS
- 22 March 2011
- journal article
- clinical trial
- Published by Ovid Technologies (Wolters Kluwer Health) in Neurology
- Vol. 76 (12), 1066-1070
- https://doi.org/10.1212/wnl.0b013e318211c537
Abstract
To report long-term results of a phase I/II study conducted in a single center in order to investigate the effect of hemopoietic stem cell transplantation (HSCT) in the treatment of multiple sclerosis (MS). Clinical and MRI outcomes of 35 patients with aggressive MS treated with HSCT are reported after a median follow-up period of 11 (range 2-15) years. Disease progression-free survival (PFS) at 15 years is 44% for patients with active CNS disease and 10% for those without (p=0.01); median time to progression was 11 (95% confidence interval 0-22) and 2 (0-6) years. Improvements by 0.5-5.5 (median 1) Expanded Disability Status Scale (EDSS) points were observed in 16 cases lasting for a median of 2 years. In 9 of these patients, EDSS scores did not progress above baseline scores. Two patients died, at 2 months and 2.5 years, from transplant-related complications. Gadolinium-enhancing lesions were significantly reduced after mobilization but were maximally and persistently diminished post-HSCT. HSCT is not a therapy for the general population of patients with MS but should be reserved for aggressive cases, still in the inflammatory phase of the disease, and for the malignant form, in which it can be life-saving. HSCT has an impressive and sustained effect in suppressing disease activity on MRI. This study provides Class IV evidence that HSCT results in PFS rates of 25%. PFS rate was significantly better in patients with active MRI lesions; HSCT also resulted in a significant reduction in the number and volume of gadolinium-enhancing lesions on MRI.This publication has 10 references indexed in Scilit:
- Early highly aggressive MS successfully treated by hematopoietic stem cell transplantationMultiple Sclerosis Journal, 2008
- Autologous stem-cell transplantation in malignant multiple sclerosis: a case with a favorable long-term outcomeMultiple Sclerosis Journal, 2007
- Autologous hematopoietic stem cell transplantation for very active relapsing-remitting multiple sclerosis: report of two casesMultiple Sclerosis Journal, 2007
- Autologous stem cell transplantation for progressive multiple sclerosis: Update of the European Group for Blood and Marrow Transplantation autoimmune diseases working party databaseMultiple Sclerosis Journal, 2006
- Survival, and time to an advanced disease state or progression, of untreated patients with moderately severe multiple sclerosis in a multicenter observational database: relevance for design of a clinical trial for high dose immunosuppressive therapy with autologous hematopoietic stem cell transplantationMultiple Sclerosis Journal, 2006
- Autologous stem cell transplantation as rescue therapy in malignant forms of multiple sclerosisMultiple Sclerosis Journal, 2005
- Thymic output generates a new and diverse TCR repertoire after autologous stem cell transplantation in multiple sclerosis patientsThe Journal of Experimental Medicine, 2005
- Multiple sclerosisBest Practice & Research Clinical Haematology, 2004
- Can the Expanded Disability Status Scale be assessed by telephone?Multiple Sclerosis Journal, 2003
- Peripheral blood stem cell transplantation in the treatment of progressive multiple sclerosis: first results of a pilot studyBone Marrow Transplantation, 1997